Skip to main content
Guobang Pharma Ltd. logo

Guobang Pharma Ltd. — Investor Relations & Filings

Ticker · 605507 ISIN · CNE100004NS2 LEI · 300300PS6T4W4PGYPM51 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 510 across all filing types
Latest filing 2026-01-27 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 605507

About Guobang Pharma Ltd.

https://www.gbgcn.com

Guobang Pharma Ltd. specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage forms. The company operates across two primary sectors: human health and animal health. Its product portfolio includes a wide range of anti-infectives, such as macrolides and quinolones, as well as cardiovascular medications and veterinary drugs like florfenicol. Guobang Pharma maintains a comprehensive industrial chain, leveraging large-scale production facilities and advanced chemical synthesis technologies to serve global markets. The organization focuses on providing integrated solutions for pharmaceutical raw materials, emphasizing quality control and regulatory compliance to meet international standards.

Recent filings

Filing Released Lang Actions
国邦医药关于首次公开发行部分限售股上市流通的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the listing and circulation of previously restricted shares following the company's initial public offering (IPO). It details the number of shares becoming freely tradable, the shareholders involved, their commitments regarding share lock-up periods, and the regulatory approvals for this share circulation. The document includes specific dates, share quantities, and shareholder commitments but does not contain financial statements or performance data. It is a formal disclosure about share circulation and lock-up expiration rather than a financial report or earnings release. This type of document fits the category of Share Issue/Capital Change (SHA), as it concerns changes in share capital availability and circulation post-IPO.
2026-01-27 Chinese
国邦医药关于第一期员工持股计划出售完毕暨终止的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion and termination of the company's first employee stock ownership plan, including details about stock purchase, lock-up period, and sale completion. It is a formal disclosure about the employee stock plan's status and subsequent arrangements, not a financial report or detailed management discussion. It does not contain financial statements or earnings data, nor is it a regulatory certification or proxy material. It fits best as a Regulatory Filing (RNS) because it is a formal regulatory announcement about corporate actions related to employee stock plans but does not fall into more specific categories like Capital/Financing Update or Transaction in Own Shares since it reports on the plan's completion and termination rather than new financing or buybacks by the company itself.
2026-01-27 Chinese
国邦医药关于股份回购进展公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from Guobang Pharmaceutical Group Co., Ltd. regarding the progress of its share repurchase program. It details the repurchase plan, including dates, amounts, purposes, and progress such as the number of shares repurchased and total amount spent. The document is relatively short (1278 characters) and focuses solely on the update of the share buyback activity. It does not contain financial statements or comprehensive financial data, nor is it an annual or interim report. The content matches the definition of a 'Transaction in Own Shares' filing, which reports on the company's buyback or sale of its own shares.
2025-12-31 Chinese
国邦医药关于第二期员工持股计划完成非交易过户暨购买完成的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the company regarding the completion of a non-trade transfer and purchase under the second employee stock ownership plan. It details the board and shareholder meetings approving the plan, the number of participants, funds raised, and the transfer of shares to the employee stock ownership plan account. It also mentions the lock-up period for the shares. This is a specific update on a capital-related transaction involving employee stock ownership, not a full financial report or earnings release. It is not a report publication announcement or a regulatory filing in the sense of certifications or compliance documents. The content fits best under Capital/Financing Update (CAP) as it relates to financing activities and capital structure changes through employee stock ownership plan implementation.
2025-12-15 Chinese
国邦医药第二期员工持股计划第一次持有人会议决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at the first holders' meeting of the company's second employee stock ownership plan. It details the meeting attendance, the approval of establishing a management committee, election of committee members, and authorization of the committee to manage the plan. There are no financial statements, earnings data, or regulatory certifications. The document is a formal announcement of meeting decisions related to an employee stock ownership plan, which does not fit into financial reports or earnings releases. It is not a proxy solicitation or voting results announcement but rather a formal meeting resolution announcement. Given the nature of the content, it best fits under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2025-12-15 Chinese
国邦医药关于第二期员工持股计划实施进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of the company's second employee stock ownership plan implementation. It details the transfer of shares to the employee stock ownership plan account and references prior board and shareholder meetings approving the plan. The document is a regulatory announcement about capital structure changes related to employee stock ownership, specifically mentioning share transfers and repurchases. It does not contain financial statements or detailed financial results, nor is it a full report or presentation. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2025-12-11 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.